文献速递骨软组织肉瘤与黑色素瘤

基于早期中期影像评估的纳武利尤单抗联合伊匹木单抗适应性给药治疗晚期黑色素瘤(ADAPT-IT研究)

Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study).
PubMed 文献 · J Clin Oncol · 2021-12-20

ADAPT-IT是一项多中心单臂II期试验,60例晚期黑色素瘤患者接受2剂纳武利尤单抗+伊匹木单抗后第6周CT评估,无新病灶且靶病灶增长≤4%者停用联合方案,否则继续标准第3、4剂。第12周RECIST 1.1缓解率48%(95%CI 35-62),中位随访25个月,18个月无进展生存率52%、总生存率80%,57%患者发生3-5级治疗相关毒性。

要点

  • 第6周CT评估无新病灶且靶病灶增长≤4%者停用联合方案,41例(68%)符合早期有利抗肿瘤效应(FATE)。
  • 第12周或之后最佳总缓解率分别为48%(95%CI 35-62)和58%(95%CI 45-71)。
  • 中位随访25个月,估计18个月无进展生存率52%、总生存率80%,57%患者出现3-5级治疗相关毒性。

核心结论

  • 标准4剂纳武利尤单抗+伊匹木单抗诱导治疗的疗效和毒性可能主要由前2剂驱动。
  • 2剂后中期CT扫描指导停止联合给药,并识别出几乎所有缓解者。
  • 需要更长随访和进一步研究来充分理解缩短纳武利尤单抗+伊匹木单抗诱导疗程的意义。

研究设计与样本

  • ADAPT-IT(NCT03122522)为多中心、单臂II期临床试验。
  • 患者接受2剂纳武利尤单抗(1 mg/kg)+伊匹木单抗(3 mg/kg),第6周行计算机断层扫描。
  • 无新病灶或靶病灶肿瘤增长≤4%者定义为方案规定的早期有利抗肿瘤效应(FATE),停止联合治疗并转为纳武利尤单抗单药。
  • 第6周无FATE者接受标准第3、4剂纳武利尤单抗+伊匹木单抗后转为纳武利尤单抗单药。
  • 主要终点为第12周RECIST 1.1缓解率,次要终点包括其他疗效评估和安全性。

主要发现

  • 共入组60例患者,41例(68%)在第6周达到FATE并符合停止纳武利尤单抗+伊匹木单抗的标准。
  • 第12周或之后任意时间RECIST最佳总缓解率分别为48%(95%CI 35-62)和58%(95%CI 45-71)。
  • 中位随访25个月,估计18个月无进展生存率为52%,总生存率为80%。
  • 57%患者发生3-5级治疗相关毒性。

临床怎么用

  • 作者认为标准4剂纳武利尤单抗+伊匹木单抗诱导治疗的疗效和毒性可能主要由前2剂驱动。
  • 作者指出2剂后中期CT扫描指导停止联合给药并识别出几乎所有缓解者。
  • 作者结论为需要更长随访和进一步研究来充分理解缩短诱导疗程的意义,原文未据此给出临床推荐。

局限性

  • 原文结论指出需要更长随访和进一步研究来充分理解缩短纳武利尤单抗+伊匹木单抗诱导疗程的意义。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Nivolumab + ipilimumab (nivo + ipi) is highly efficacious but has high toxicity. Standard treatment in advanced melanoma is four doses of nivo + ipi followed by nivo alone. Whether four doses of nivo + ipi are needed is unclear. METHODS: The Adaptively Dosed ImmunoTherapy Trial (ADAPT-IT) study (NCT03122522) is a multicenter, single-arm phase II clinical trial. Patients received two doses of nivo (1 mg/kg) + ipi (3 mg/kg) followed by a computed tomography scan at week 6. Patients without new lesions or index lesion tumor growth of > 4% had protocol-defined early favorable antitumor effect (FATE) and ceased nivo + ipi, transitioning to nivo monotherapy. Patients without FATE at week 6 received the standard third and fourth doses of nivo + ipi followed by nivo monotherapy. The primary end point was response rate by RECIST 1.1 at week 12. Secondary end points included additional efficacy assessments and safety. RESULTS: Sixty patients were enrolled; 41 patients (68%) had FATE at week 6 and met criteria for stopping nivo + ipi. Best overall response rates by RECIST at week 12 or any time afterward were 48% (95% CI, 35 to 62) and 58% (95% CI, 45 to 71), respectively. With a median follow-up of 25 months, the estimated 18-month progression-free survival and overall survival are 52% and 80%, respectively. Fifty seven percent of patients had grade 3-5 treatment-related toxicity. CONCLUSION: The efficacy and toxicity of standard four dose nivo + ipi induction therapy in melanoma is likely driven by the first two doses. An interim computed tomography scan after two doses guided cessation of combination dosing and identified almost all responders. Longer follow-up and further study are needed to fully understand the implications of a shortened induction course of nivo + ipi.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Postow MA, Goldman DA, Shoushtari AN, et al. Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study). J Clin Oncol. 2021. PMID: 34928709. doi:10.1200/JCO.21.01570

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。